The eye does not have a way to remove floaters, so you will have them as long as you live unless you do something about it.

I am a 67-year-old male with generally good vision. I have had a few floaters in my eyes over the years, but they have generally been small and have ...

ResMed’s strong demand for AirSense 11 boosts its earnings outlook. Learn why RMD stock is undervalued with growth ...

Are concerns about sleeping pills being linked to dementia based on evidence? Many people need help getting to, or staying, ...

Ken Fisher is the founder and executive chairman of Fisher Asset Management, a renowned investment and financial analysis ...

Ratings has upgraded the issuer rating and senior unsecured notes ratings of global pharmaceutical company Eli Lilly and ...

An implant for sleep apnea is one of the few CPAP alternatives. This article compares hypoglossal nerve stimulation and ...

As Eli Lilly ends the year with Zepbound in good supply, TD Cowen analyst Steve Scala asked CEO David Ricks if the company ...

Comments: Growth in the quarter was driven by Mounjaro, with sales up 60% to $3.5 billion, and Zepbound, with sales of $1.9 billion. New Products revenue, which consists of Ebglyss, Jaypirca, Kisunla, ...

Eli Lilly has invested heavily into obesity, dominating the landscape—alongside semaglutide maker Novo Nordisk—with its ...

Terence Flynn, Morgan Stanley, inquired about Zepbound payer dynamics and access. Patrik Jonsson explained that Medicare coverage related to obstructive sleep apnea (OSA) is anticipated in the second ...

Lilly's fourth-quarter profit doubles, driven by diabetes and obesity treatments. Strong revenue and forecast for 2025.